Metastatic chest wall malignant schwannoma responding to sorafenib: Case report and literature review

Cancer Biology and Therapy

Volumn 7, Issue 6, 2008, Pages 810-813

  Gudena, Vinay ^a   Verma, Nitin ^a   Post, Ginell ^a   Kizziah, Michael ^b   Fenning, Robert ^a   Montero, Alberto J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Malignant peripheral nerve sheath tumor; Ras; Schwannoma; Sorafenib; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LUNG NODULE; MALIGNANT NEURILEMOMA; NERVE SHEATH TUMOR; NEUROFIBROMA; NUCLEAR MAGNETIC RESONANCE IMAGING; THORAX WALL CANCER; TREATMENT RESPONSE; BRAIN TUMOR; LUNG TUMOR; METASTASIS; NEURILEMOMA; PATHOLOGY; THORAX RADIOGRAPHY; THORAX WALL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRAIN NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; PROTEIN KINASE INHIBITORS; PYRIDINES; RADIOGRAPHY, THORACIC; THORACIC WALL; TREATMENT OUTCOME;

EID: 46749109971     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.6.5932     Document Type: Article

References (29)

1. D'Agostino AN, Soule EH and Miller RH. Primary Malignant Neoplasms of Nerves (Malignant Neurilemomas) in Patients without Manifestations of Multiple Neurofibromatosis (Von Recklinghausen's Disease). Cancer 1963; 16:1003-14.
2. Huson SM, Compston DA and Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales II. Guidelines for genetic counselling. J Med Genet 1989; 26:712-21.
3. Ducatman BS, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006-21.
4. Davidson KG, Walbaum PR and McCormack RJ. Intrathoracic neural tumours. Thorax 1978; 33:359-67.
5. Evans DG, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39:311-4.
6. Ferner RE, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44:81-8.
7. Mrugala MM, Batchelor TT and Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 2005; 18:604-10.
8. Menon AG, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 1990; 87:5435-9.
9. Friedrich RE, Keiner D and Hagel C. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1. Anticancer Res 2007; 27:2085-90.
10. Holtkamp N, et al. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol (Berl) 2004; 107:159-68.
11. Oosterwijk WM and Swierenga J. Neurogenic tumours with an intrathoracic localization. Thorax 1968; 23:374-84.
12. Reed JC, Hallet KK and Feigin DS. Neural tumors of the thorax: subject review from the AFIP. Radiology 1978; 126:9-17.
13. McClenathan JH and Bloom RJ. Peripheral tumors of the intercostal nerves. Ann Thorac Surg 2004; 78:713-4.
14. Bhattacharyya AK, Perrin R and Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol 2004; 69:335-49.
15. Beeram M, Patnaik A and Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771-90.
16. Carlomagno F, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98:326-34.
17. Liu L, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851-8.
18. Packer RJ, et al. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002; 58:1461-70.
19. Ferner RE and Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002; 62:1573-7.
20. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109.
21. Farrar MA, Alberol I and Perlmutter RM. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 1996; 383:178-81.
22. Hoyos B, et al. Activation of c-Raf kinase by ultraviolet light. Regulation by retinoids. J Biol Chem 2002; 277:23949-57.
23. Kasid U, et al. Activation of Raf by ionizing radiation. Nature 1996; 382:813-6.
24. Kolch W, et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993; 364:249-52.
25. Luo Z, et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 1996; 383:181-5.
26. Stancato LF, et al. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol 1997; 17:3833-40.
27. Tilbrook PA, et al. Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch Biochem Biophys 2001; 396:128-32.
28. Yao B, et al. Phosphorylation of Raf by ceramide-activated protein kinase. Nature 1995; 378:307-10.
29. Cornwell MM and Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 1993; 268:15347-50.